Clinical Evaluation of a Test for Monitoring the Recurrence of Bladder Cancer

CompletedOBSERVATIONAL
Enrollment

424

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

February 28, 2019

Study Completion Date

May 31, 2019

Conditions
Bladder Cancer
Interventions
DEVICE

Xpert Bladder Cancer Monitor

in vitro diagnostic test for the recurrence of bladder cancer in patients that have been previously diagnosed with bladder cancer

Trial Locations (17)

23235

Virginia Urology, Richmond

59808

Five Valleys Urology, Missoula

60160

UroPartners, Melrose Park

73104

Stephenson Cancer Center, Oklahoma City

75390

UT Southwestern, Dallas

80113

Urology Associates, P.C., Englewood

80211

The Urology Center of Colorado, P.C., Denver

83642

Idaho Urologic Institute, Meridian

83814

North Idaho Urology, Coeur d'Alene

94304

PAVA, Palo Alto

10065-4896

Weill Cornell Medicine, New York

L4M 7G1 CA

The Male/Female Health and Research Centre, Barrie

L7N 3V2

G Kenneth Jansz Medicine Professional Corp., Burlington

N2N 2B9 CA

Urology Associates / Urologic Medical Research, Kitchener

P1B 7K8

Urology Clinic of Dr. Goldfarb, North Bay

M2J 1V1

Urologic Clinic of Stanley Flax, North York

6525GA

Radboud University Medical Center, Nijmegen

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cepheid

INDUSTRY

NCT03125460 - Clinical Evaluation of a Test for Monitoring the Recurrence of Bladder Cancer | Biotech Hunter | Biotech Hunter